Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 21;12:761–770. doi: 10.2147/DMSO.S204439

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Kunavisarut et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

(A) Plasma glucose and (B) plasma insulin levels during OGTTs in patients in the MFM-SUF and NGT groups. Notes: For the MFM-SUF group, the OGTT was performed three times, while taking the maximum dosage of sulfonylurea (Max-SU), discontinuing sulfonylurea (Discont-SU), and taking 25% of the maximum dosage of sulfonylurea (25%Max-SU). During the treatment with Max-SU, all MFM-SUF patients had significantly higher fasting plasma insulin levels than did the subjects with NGT, but the plasma insulin response to OGTT in Max-SU was much lower than in the NGT group. Abbreviations: MSM-SUF, maximum dosages of metformin and sulfonylurea; NGT, normal glucose tolerance; OGTT, oral glucose tolerance test; SU, sulfonylurea.